Fig 1.
CONSORT flow chart of the study.
Table 1.
Basal characteristics of the study population divided into active treatment and placebo, as compared to the total study population.
Fig 2.
IGF-1 in the active and the placebo groups at the inclusion compared to after 48 months.
Fig 3.
IGF-1 concentration in the active treatment and the placebo groups at the start and at the end of the intervention.
Fig 4.
IGF-1 SD score in the active and the placebo groups at inclusion compared to after 48 months.
Fig 5.
IGF-1 SD score at inclusion on the active treatment and in the placebo groups at the start and at the end of the intervention.
Fig 6.
Response to IGF-1 of supplementation with selenium and coenzyme Q10 in those with a basal selenium concentration in the lowest quartile (Fig 6a), and in those with a basal selenium concentration in the highest quartile (Fig 6b).
Fig 7.
IGFBP-1 in the active and the placebo groups at inclusion compared with after 48 months.
Fig 8.
IGFBP-1 concentration in the active treatment and the placebo groups at the start and at the end of the intervention.